World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
48735
World Ranking
11525
National Ranking
465

Overview

Natasha B. Leighl is affiliated with the Princess Margaret Cancer Centre in Canada and has made significant contributions to the field of medicine, specifically within pulmonary and respiratory medicine, oncology, and cancer research.

Their research focuses mainly on lung cancer treatments and mutations, lung cancer diagnosis and treatment, cancer genomics and diagnostics, lung cancer research studies, and cancer immunotherapy and biomarkers. Additional interests include colorectal cancer treatments and studies as well as gastric cancer management and outcomes.

Natasha B. Leighl has published extensively, with a notable presence in prominent medical journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Lung Cancer
  • Current Oncology

Their collaborative work involves a group of frequent co-authors, demonstrating long-term research partnerships. These include:

  • Frances A. Shepherd
  • Adrian G. Sacher
  • Geoffrey Liu
  • Penelope A. Bradbury
  • Ming-Sound Tsao

Significant recent papers authored by Natasha B. Leighl or co-authored in the field are as follows:

  • Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, 2021, Journal of Clinical Oncology
  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer, 2021, Journal of Thoracic Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2020, Journal of Clinical Oncology
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, 2021, Journal of Clinical Oncology
  • Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153, 2020, Journal of Clinical Oncology

Leighl's body of work contributes to the understanding and treatment protocols of advanced lung cancer, including targeted therapies and immunotherapy options. Their research is grounded in clinical oncology with a strong focus on improving diagnostic and therapeutic strategies.

Overall, Natasha B. Leighl's contributions span multiple subfields including molecular biology and radiology, nuclear medicine, and imaging, reinforcing a multidisciplinary approach to cancer research and treatment.

Best Publications

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

    Martin Reck;Joachim von Pawel;Petr Zatloukal;Rodryg Ramlau

  • Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

    Thomas J. Smith;Kari Bohlke;Gary H. Lyman;Kenneth R. Carson

  • Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    M. Reck;J Von Pawel;P. Zatloukal;R. Ramlau

  • Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Edward B. Garon;Matthew D. Hellmann;Naiyer A. Rizvi;Enric Carcereny

  • Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

    James D McKay;Rayjean J Hung;Younghun Han;Xuchen Zong

  • Sensitive tumour detection and classification using plasma cell-free DNA methylomes

    Shu Yi Shen;Rajat Singhania;Gordon Fehringer;Ankur Chakravarthy

  • Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis

    Rebecca G. Hagerty;Phyllis N. Butow;Peter M. Ellis;Elizabeth A. Lobb

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • Cancer patient preferences for communication of prognosis in the metastatic setting.

    Rebecca G. Hagerty;Phyllis N. Butow;Peter A. Ellis;Elizabeth A. Lobb

  • Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

    Natasha B. Leighl;Ray D. Page;Victoria M. Raymond;Davey B. Daniel

  • Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature

    Giannicola D'Addario;Melania Pintilie;Natasha B. Leighl;Ronald Feld

  • Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

    Massimo Di Maio;Ciro Gallo;Natasha B. Leighl;Maria Carmela Piccirillo

  • Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

    Keunchil Park;Eric B Haura;Natasha B Leighl;Paul L R Mitchell

  • Perceptions of palliative care among patients with advanced cancer and their caregivers

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Natasha Leighl

  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    Christian Rolfo;Philip Mack;Giorgio V. Scagliotti;Charu Aggarwal

  • Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

    Nasser H. Hanna;Bryan J. Schneider;Sarah Temin;Sherman Baker

Frequent Co-Authors

Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Geoffrey Liu
Geoffrey Liu Princess Margaret Cancer Centre
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Wei Xu
Wei Xu Shenzhen University
Suzanne Kamel-Reid
Suzanne Kamel-Reid University Health Network
Andrea Bezjak
Andrea Bezjak Princess Margaret Cancer Centre
Lesley Seymour
Lesley Seymour Queen's University
Melania Pintilie
Melania Pintilie Princess Margaret Cancer Centre
Jeffrey S. Hoch
Jeffrey S. Hoch University of California, Davis
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in advancing your medical career or exploring alternative paths? The field of healthcare offers a variety of online degrees tailored for different interests and schedules. For those looking to enter management and leadership roles in hospitals or clinics, a master's in healthcare administration online provides training in organizational leadership, policy, and operations.

Nurses aiming to reach the highest levels of clinical practice can consider the most affordable online dnp programs. These programs focus on advancing clinical expertise and leadership skills in nursing practice. Pharmacists seeking a flexible and accelerated track may benefit from the 3 year online pharmd, which enables working professionals to earn their doctorate at an expedited pace.

For those interested in the digital side of healthcare, accredited him programs offer a pathway into health information management, blending technology, administration, and healthcare knowledge. Exploring these options can expand your career opportunities while offering the flexibility of online study.

Best Scientists Citing Natasha B. Leighl

Trending Scientists